Dyne Therapeutics Inc
DYN9.400USD
+0.070+0.75%
收盘 07/17, 16:00（美东）报价延迟15分钟
1.07B总市值
亏损市盈率 TTM
关于 Dyne Therapeutics Inc 公司
Dyne Therapeutics Inc. 是一家临床阶段的肌肉疾病公司。该公司专注于为患有遗传性疾病的人提供改变生活的疗法。该公司正在利用其 FORCE 平台克服肌肉组织输送和肌肉疾病寡核苷酸疗法的局限性。其 FORCE 平台疗法由寡核苷酸有效载荷组成，旨在针对疾病的遗传基础。该公司利用其 FORCE 平台组建了一系列肌肉疾病疗法，包括其在 1 型肌强直营养不良症 (DM1)、杜氏肌营养不良症 (DMD) 和面肩肱型营养不良症 (FSHD) 方面的领先项目。其疗法由三个部分组成：Fab、经过临床验证的连接体和使用连接体连接到 Fab 的寡核苷酸有效载荷。该公司还计划通过专注于罕见骨骼肌疾病以及心脏和代谢性肌肉疾病的开发工作来扩大其产品组合。
公司简介
公司代码DYN
公司名称Dyne Therapeutics Inc
上市日期Sep 17, 2020
成立日期2013
CEOMr. John Cox
员工数量191
证券类型Ordinary Share
年结日Sep 17
公司地址1560 Trapelo Road
城市WALTHAM
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编02451
电话17817868230
网址https://dyne-tx.com/
公司代码DYN
上市日期Sep 17, 2020
成立日期2013
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. John Cox
Mr. John Cox
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
97.96K
+158.06%
Dr. Catherine Stehman-Breen, M.D.
Dr. Catherine Stehman-Breen, M.D.
Independent Director
Independent Director
89.47K
--
Dr. Oxana Beskrovnaya, Ph.D.
Dr. Oxana Beskrovnaya, Ph.D.
Chief Innovation Officer
Chief Innovation Officer
43.00K
-65.20%
Mr. Erick J. Lucera
Mr. Erick J. Lucera
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
Mr. David C. Lubner
Mr. David C. Lubner
Independent Director
Independent Director
--
--
Ms. Johanna Friedl- Naderer
Ms. Johanna Friedl- Naderer
Chief Commercial Officer
Chief Commercial Officer
--
--
Dr. Carlo Incerti, M.D.
Dr. Carlo Incerti, M.D.
Independent Director
Independent Director
--
--
Mr. Dirk Kersten
Mr. Dirk Kersten
Independent Director
Independent Director
--
--
Dr. Doug Kerr
Dr. Doug Kerr
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Jason Rhodes
Mr. Jason Rhodes
Independent Chairman of the Board
Independent Chairman of the Board
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. John Cox
Mr. John Cox
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
97.96K
+158.06%
Dr. Catherine Stehman-Breen, M.D.
Dr. Catherine Stehman-Breen, M.D.
Independent Director
Independent Director
89.47K
--
Dr. Oxana Beskrovnaya, Ph.D.
Dr. Oxana Beskrovnaya, Ph.D.
Chief Innovation Officer
Chief Innovation Officer
43.00K
-65.20%
Mr. Erick J. Lucera
Mr. Erick J. Lucera
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
Mr. David C. Lubner
Mr. David C. Lubner
Independent Director
Independent Director
--
--
Ms. Johanna Friedl- Naderer
Ms. Johanna Friedl- Naderer
Chief Commercial Officer
Chief Commercial Officer
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 5月17日 周六
更新时间: 5月17日 周六
持股股东
股东类型
持股股东
持股股东
占比
Janus Henderson Investors
7.51%
RA Capital Management, LP
7.05%
Atlas Venture
6.62%
The Vanguard Group, Inc.
5.36%
BlackRock Institutional Trust Company, N.A.
4.54%
Other
68.92%
持股股东
持股股东
占比
Janus Henderson Investors
7.51%
RA Capital Management, LP
7.05%
Atlas Venture
6.62%
The Vanguard Group, Inc.
5.36%
BlackRock Institutional Trust Company, N.A.
4.54%
Other
68.92%
股东类型
持股股东
占比
Investment Advisor/Hedge Fund
27.04%
Venture Capital
20.92%
Investment Advisor
19.50%
Hedge Fund
15.36%
Private Equity
3.46%
Research Firm
2.73%
Sovereign Wealth Fund
0.69%
Individual Investor
0.61%
Corporation
0.22%
Other
9.46%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
430
125.53M
91.24%
+6.97M
2025Q1
444
126.02M
110.93%
+6.11M
2024Q4
417
114.24M
101.08%
-7.86M
2024Q3
400
113.88M
111.83%
-6.47M
2024Q2
373
112.89M
113.78%
+7.88M
2024Q1
324
97.50M
111.98%
+21.84M
2023Q4
282
72.67M
118.28%
-4.07M
2023Q3
268
67.80M
111.02%
+90.07K
2023Q2
267
66.99M
114.89%
+4.15M
2023Q1
269
62.13M
106.57%
+3.08M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Janus Henderson Investors
10.35M
7.51%
+2.97M
+40.30%
Mar 31, 2025
RA Capital Management, LP
9.71M
7.05%
+3.33M
+52.24%
Mar 31, 2025
Atlas Venture
9.13M
6.62%
+1.11M
+13.86%
Mar 31, 2025
The Vanguard Group, Inc.
7.39M
5.36%
+697.86K
+10.43%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
6.26M
4.54%
+96.01K
+1.56%
Mar 31, 2025
Forbion Capital Partners
5.46M
3.96%
--
--
Mar 31, 2025
Fidelity Management & Research Company LLC
5.19M
3.77%
-2.39M
-31.52%
Mar 31, 2025
Braidwell LP
3.62M
2.63%
+2.94M
+431.63%
Mar 31, 2025
State Street Global Advisors (US)
3.61M
2.62%
-107.73K
-2.90%
Mar 31, 2025
Citadel Advisors LLC
3.01M
2.18%
+147.81K
+5.17%
Mar 31, 2025
查看更多
持股ETF
更新时间: 7月6日 周日
更新时间: 7月6日 周日
机构名称
占比
iShares Neuroscience and Healthcare ETF
2.39%
Virtus LifeSci Biotech Clinical Trials ETF
0.62%
Tema Neuroscience and Mental Health ETF
0.55%
SPDR S&P Biotech ETF
0.28%
Direxion Daily S&P Biotech Bull 3X Shares
0.26%
Invesco Nasdaq Biotechnology ETF
0.15%
iShares Health Innovation Active ETF
0.14%
ProShares Ultra Nasdaq Biotechnology
0.12%
Optimize Strategy Index ETF
0.12%
iShares Biotechnology ETF
0.11%
查看更多
iShares Neuroscience and Healthcare ETF
占比2.39%
Virtus LifeSci Biotech Clinical Trials ETF
占比0.62%
Tema Neuroscience and Mental Health ETF
占比0.55%
SPDR S&P Biotech ETF
占比0.28%
Direxion Daily S&P Biotech Bull 3X Shares
占比0.26%
Invesco Nasdaq Biotechnology ETF
占比0.15%
iShares Health Innovation Active ETF
占比0.14%
ProShares Ultra Nasdaq Biotechnology
占比0.12%
Optimize Strategy Index ETF
占比0.12%
iShares Biotechnology ETF
占比0.11%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
